RxDoctor Payments Data

Rupal Oquinn, MD

Internal Medicine · Philadelphia, PANPI 1033319991

Payments from drug & device makers

$23,729in general payments, 2019–2025

Across 47 payments — averaging $504.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$11K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$6K
  • Astrazeneca UK Limited$6K
  • Impulse Dynamics (USA) Inc.$289
  • Johnson & Johnson$45
  • Atricure, Inc.$38
  • plus $66 from 3 others

What the payments were for

  • Consulting fees$15,82567%
  • Speaking & faculty fees$6,00025%
  • Travel & lodging$3461%
  • Food & beverage$1,5587%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,729 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$184,496
Medicare patients
1,299
Services billed
2,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$111,221
EntrestoSacubitril/Valsartan49$74,510
XareltoRivaroxaban49$55,610
Repatha SureclickEvolocumab87$54,830
JardianceEmpagliflozin37$48,773
FarxigaDapagliflozin Propanediol19$27,547
Praluent PenAlirocumab34$20,168
Rosuvastatin Calcium617$10,314
BrilintaTicagrelor12$7,781
Metoprolol Succinate263$4,025
Atorvastatin Calcium296$3,757
Ezetimibe93$3,378
Valsartan82$2,946
Midodrine Hcl16$2,397
Omega-3 Acid Ethyl Esters31$2,280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$45$55,61049 claims
Boehringer IngelheimJardiance$22$48,77337 claims
AstraZenecaFarxiga, Brilinta$10,854$35,32831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →